Company intelligence / Profile preview
LigaChem Biosciences
Daejeon, South Korea
- Ownership
- Public · A141080
- Employees
- ~170
- Development stage
- Other
01
Overview
LigaChem Biosciences has validated its proprietary ADC linker technology in preclinical models and multiple licensing partners are advancing candidates (e.g., LRRC15 ADC, CA242 ADC) towards clinical trials; its in-house immuno-oncology STING agonist (LCB39) is planned for entry into clinical trials in early 2026, with promising preclinical safety and efficacy[4].
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateSmall molecule
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
Request access →03
Partnerships
Beyond the preview
Go deeper on LigaChem Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LigaChem Biosciences.